Pediatric Preclinical Testing Program

 

The Pediatric Preclinical Testing Program (PPTP) is a comprehensive program to systematically evaluate new agents against childhood solid tumor and leukemia models. The PPTP is supported through an NCI research contract to The Research Institutte at Nationwide Children's Hospital with Dr. Peter Houghton as the Principal Investigator. Testing occurs both at The Research Institute and also at subcontract sites that have expertise in specific childhood cancers.

 

The primary goal of the PPTP is to identify new agents that have the potential for significant activity when clinically evaluated against selected childhood cancers.

 

The program is based on a substantial body of data showing that appropriate childhood cancer preclinical in vivo models can recapitulate the anti-tumor activity of known effective agents and can prospectively identify novel agents subsequently shown to have clinical activity against specific cancers of children and adolescents. By facilitating development of a more reliable pediatric new agent prioritization process, the Pediatric Preclinical Testing Program will contribute to the goal of identifying more effective treatments for children with cancer.

 

PPTP Principal Investigators

  • Dr. Peter Houghton, PhD — Greehey Children's Cancer Research Institute
  • Dr. E. Anders Kolb, MD — A.I duPont Children’s Hospital,Wilmington
  • Dr. Richard Gorlick, MD — Children's Hospital at Montefiore, Albert Einstein College of Medicine
  • Dr. Stephen Keir, PhD — Preston Robert Tisch Brain Tumor Center, Duke University
  • Dr. John Maris, MD — Children's Hospital of Philadelphia
  • Dr. Richard Lock, PhD — Children's Cancer Institute, Randwick, Australia
  • Dr. C. Patrick Reynolds, MD, PhD — Texas Tech University Health Science Center, Lubbock

 

 

 

Data regarding the Pediatric Preclinical Testing Program:

 

 

Visual representation of tumor sensitivity based on the difference of individual tumor lines from the midpoint response (stable disease). Bars to the right of the median represent lines that are more sensitive (objective response), and to the left are tumor models that are less sensitive (progressive disease). Red bars indicate lines with a significant difference in EFS distribution between treatment and control groups, while blue bars indicate lines for which the EFS distributions were not significantly different.

 

 

 

Raushan T. Kurmasheva, Ph.D. | PPTP Program Manager

Greehey Children's Cancer Rsearch Institute,
UT Health San Antonio San Antonio
8403 Floyd Curl Dr.
San Antonio, Texas 78229

Tel: 1.210.562.9155